RNA polymerase II subunit J2Genealiases: HRPB11B · RPB11b1
Q-omics provides the consensus-scored POLR2J2 profile across patient tissues and cancer cell-line models. POLR2J2 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, POLR2J2 is differentially expressed in 2, with the highest sampling consensus in ESCA. Additionally, POLR2J2 RNA expression shows 9,224 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight SCLC, ESCA, and HNSC as cancer lineages where POLR2J2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for POLR2J2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes POLR2J2 survival associations across molecular data types. POLR2J2 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible POLR2J2 RNA expression–survival associations across cancer types. High POLR2J2 expression shows unfavorable associations in STAD, KIRC, MESO and UVM, but favorable associations in SCLC and PAAD. The SCLC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SCLC as the clearest survival context for POLR2J2 RNA expression.
This table summarizes POLR2J2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for POLR2J2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. POLR2J2 shows higher tumor expression in ESCA and LIHC. The ESCA box plot shows higher POLR2J2 RNA expression in tumor versus normal tissue (log2 FC = +0.083, t-test p = .049).
This table shows molecular features associated with POLR2J2 in patient tissues and cancer cell lines. In patient samples, POLR2J2 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, POLR2J2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LIVER.
